Oncorus Appoints Douglas Fambrough to Board of Directors
June 23 2022 - 7:00AM
Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company
focused on driving innovation to transform outcomes for cancer
patients, today announced the appointment of Douglas M. Fambrough,
III, Ph.D. to its board of directors.
“We are thrilled to welcome Doug to our board and leverage his
significant expertise and executive leadership skills as we work to
advance our next-generation HSV and selectively self-amplifying
vRNA/LNP platforms,” said Theodore (Ted) Ashburn, M.D., Ph.D.,
President and Chief Executive Officer of Oncorus. “As a recognized
industry leader with extensive experience in RNA medicines and
growing successful biotechnology companies, Doug’s appointment
highlights Oncorus’ commitment to bringing together innovators of
our industry as we progress our pipeline and build upon our
platforms. We look forward to working with Doug as we advance our
portfolio of differentiated viral immunotherapies to help
meaningfully improve the lives of cancer patients.”
“Oncorus’ novel technology is generating a pipeline of uniquely
engineered viruses and first-in-class vRNA product candidates. I’m
excited to partner with this exceptional team to progress their
portfolio of viral immunotherapies and unlock the potential of this
modality to activate multiple arms of the immune system, realizing
the promise of this new class of medicines in oncology,” said Dr.
Fambrough. “I look forward to working with my fellow board members
and Oncorus’ leadership team to advance this potentially
paradigm-shifting approach to cancer treatment.”
Dr. Fambrough brings over 25 years of clinical and managerial
experience to Oncorus. Most recently, he served as co-founder,
President and Chief Executive Officer of Dicerna Pharmaceuticals, a
publicly traded biotechnology company focused on RNAi-based
therapeutics for various disease areas, including oncology. At
Dicerna, he was responsible for overseeing the company’s scientific
and business success for nearly 12 years leading up to its
acquisition by Novo Nordisk in December 2021 for $3.3 billion.
Prior to Dicerna, Dr. Fambrough was a general partner at Oxford
Bioscience Partners, where he has specialized in financing
innovative life science technology companies. While at Oxford, Dr.
Fambrough led the investment in the first-generation RNA
interference company Sirna Therapeutics and other pioneering
biotechnology companies, including Solexa, Xencor, Rib-X
Pharmaceuticals, and Solstice Neurosciences. Prior to joining
Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT
Center for Genomic Research, now known as the Broad Institute. He
holds an A.B. in biology from Cornell University and a Ph.D. in
genetics from the University of California, Berkeley.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver
next-generation viral immunotherapies to transform outcomes for
cancer patients. We are advancing a portfolio of intratumorally
(iTu) and intravenously (IV) administered viral immunotherapies for
multiple indications with significant unmet need based on our
Herpes Simplex Virus (HSV) and selectively self-amplifying viral
RNA Immunotherapy Platforms.
Designed to deliver next-generation viral immunotherapy impact,
our HSV Platform improves upon key characteristics of this
therapeutic class to enhance systemic activity. Our lead HSV
program, ONCR-177, is designed to be directly administered into a
tumor, resulting in high local concentrations of the therapeutic
agent and its five encoded transgenes, as well as low systemic
exposure to the therapy, which could limit systemic toxicities. Our
pioneering selectively self-amplifying viral RNA (vRNA)
Immunotherapy Platform, highlighted by our product candidates
ONCR-021 and ONCR-788, involves a highly innovative, novel
combination of RNA and oncolytic virus-based modalities designed to
realize the potential of RNA medicines for cancer.
Please visit www.oncorus.com to learn more.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, implied and
express statements regarding the therapeutic potential of Oncorus’
product candidates and the potential that viral immunotherapy
modalities will activate multiple arms of the immune system. The
words “may,” “might,” “will,” “could,” “would,” “should,” “expect,”
“plan,” “anticipate,” “intend,” “believe,” “expect,” “estimate,”
“seek,” “predict,” “future,” “project,” “potential,” “continue,”
“target” and similar words or expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Any forward-looking
statements in this press release are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, risks associated with: Oncorus’
ability to successfully demonstrate the safety, tolerability and
efficacy of ONCR-177, ONCR-021, ONCR-788 and ONCR-GBM and obtain
regulatory approval thereof; the impact of COVID-19 on Oncorus’
operations and the timing and anticipated results of its ongoing
and planned clinical trials; Oncorus’ ability to obtain the
requisite components for its product candidates manufactured in
accordance with regulatory requirements; Oncorus’ planned facility
consolidation and the expansion of Oncorus’ in-house manufacturing
capabilities; the adequacy of Oncorus’ existing capital resources
and availability of financing on commercially reasonable terms; the
accuracy of the Oncorus’ estimates regarding expenses, future
revenue, capital requirements and needs for additional financing;
and Oncorus’ ability to obtain, maintain and protect its
intellectual property. These and other risks and uncertainties are
described in greater detail in the section entitled "Risk Factors"
in Oncorus’ Annual Report on Form 10-K for the year ended December
31, 2021, filed with the Securities and Exchange Commission (SEC)
on March 9, 2022, and Oncorus’ Quarterly Report on Form 10-Q for
the quarter ended March 31, 2022, filed with the SEC on May 4,
2022, and in any subsequent filings that Oncorus makes with the
SEC. These documents are available under the “SEC filings” page of
the Investors section of Oncorus’ website at
http://investors.oncorus.com. Any forward-looking statements
represent Oncorus’ views only as of the date of this press release
and should not be relied upon as representing its views as of any
subsequent date. Oncorus explicitly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking
statements.Investor Contact:Stern Investor
Relations Julie SeidelJulie.seidel@sternir.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jul 2023 to Jul 2024